13 results on '"Ascierto, M"'
Search Results
2. Correction to: Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop (Journal for ImmunoTherapy of Cancer (2020) 7 (131) DOI: 10.1186/s40425-019-0602-4)
- Author
-
Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K. -K., Ziv, E., Chowell, D., Coussens, L. M., De Carvalho, D. D., Denardo, D. G., Galon, J., Kaufman, H. L., Kirchhoff, T., Lotze, M. T., Luke, J. J., Minn, A. J., Politi, K., Shultz, L. D., Simon, R., Thorsson, V., Weidhaas, J. B., Ascierto, M. L., Ascierto, P. A., Barnes, J. M., Barsan, V., Bommareddy, P. K., Bot, A., Church, S. E., Ciliberto, G., De Maria, A., Draganov, D., W. S., Ho, Mcgee, H. M., Monette, A., Murphy, J. F., Nistico, P., Park, W., Patel, M., Quigley, M., Radvanyi, L., Raftopoulos, H., Rudqvist, N. -P., Snyder, A., Sweis, R. F., Valpione, S., Zappasodi, R., Butterfield, L. H., Disis, M. L., Fox, B. A., Cesano, A., and Marincola, F. M.
- Published
- 2019
3. 1203P - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours
- Author
-
Massard, C., Cassier, P., Bendell, J.C., Marie, D.B., Blery, M., Morehouse, C., Ascierto, M., Zerbib, R., Mitry, E., and Tolcher, A.W.
- Published
- 2019
- Full Text
- View/download PDF
4. NEMO-binding domain peptide inhibits proliferation of human melanoma cells
- Author
-
IANARO, ANGELA, IALENTI, ARMANDO, M. Tersigni, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, DE MAIO, ANNA, Ombra M, Gentilcore G, Capone M, Ascierto M, Satriano RA, Farina B, FARAONE MENNELLA, MARIA ROSARIA, Ascierto PA, Ianaro, A, Tersigni, M, Belardo, G, Martino, Sd, Napolitano, M, Palmieri, G, Sini, M., DE MAIO, Anna, Ombra, M, Gentilcore, G, Capone, M, Ascierto, M, Satriano, Ra, Farina, B, FARAONE MENNELLA, MARIA ROSARIA, Ascierto, Pa, Ialenti, A., Ianaro, Angela, M., Tersigni, Di Martino, S, Sini, M, and Ialenti, Armando
- Subjects
NEMO ,melanoma - Abstract
Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-kB (NF-kB) pathway. In vitro studies have shown that NF-kB binding is constitutively elevated in human melanoma cultures compared to normal elanocytes. It has been found that a short cell-permeable peptide spanning the IKK-beta NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFalpha-induced NF-kB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-kB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-kB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-kB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.
- Published
- 2009
5. PARP1 as apoptosis marker in A375 melanoma cells treated with NEMO binding domain peptide
- Author
-
DE MAIO, ANNA, NATALE, EMILIANA, MISTRETTA, CARMELA, IANARO, ANGELA, FARAONE MENNELLA, MARIA ROSARIA, De Martino S., Napolitano M., Gentilcore G., Capone M., Tersigni M. R., Ascierto M. L., Ciccariello L., Palmieri G., Ialenti A., Ascierto P. A., Farina B., Di Girolamo M, DE MAIO, Anna, Natale, Emiliana, Mistretta, Carmela, De Martino, S., Napolitano, M., Ianaro, Angela, Gentilcore, G., Capone, M., Tersigni, M. R., Ascierto, M. L., Ciccariello, L., Palmieri, G., Ialenti, A., Ascierto, P. A., Farina, B., and FARAONE MENNELLA, MARIA ROSARIA
- Published
- 2008
6. PolyADPribosylation reaction in melanoma cells treated with NEMO( NF-kB essential modulator) binding domain peptide
- Author
-
DE MAIO, ANNA, NATALE, EMILIANA, FARAONE MENNELLA, MARIA ROSARIA, Mistretta C., Di Martino S., Gentilcore G., Capone M., Ascierto M. L., Palmieri G., Ascierto P. A., Farini B., DE MAIO, Anna, Natale, Emiliana, Mistretta, C., Di Martino, S., Gentilcore, G., Capone, M., Ascierto, M. L., Palmieri, G., Ascierto, P. A., Farini, B., and FARAONE MENNELLA, MARIA ROSARIA
- Published
- 2008
7. BI-14 * GENOMIC PROFILING OF A PREDICTIVE SIGNATURE FOR MET-TARGETED THERAPY IN GLIOBLASTOMA
- Author
-
Johnson, J., primary, Ascierto, M. L., additional, Newsome, D., additional, Mittal, S., additional, Kang, L., additional, Briggs, M., additional, Tanner, K., additional, Berens, M. E., additional, Marincola, F. M., additional, Vande Woude, G. F., additional, and Xie, Q., additional
- Published
- 2014
- Full Text
- View/download PDF
8. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
- Author
-
Bedognetti, D, primary, Spivey, T L, additional, Zhao, Y, additional, Uccellini, L, additional, Tomei, S, additional, Dudley, M E, additional, Ascierto, M L, additional, De Giorgi, V, additional, Liu, Q, additional, Delogu, L G, additional, Sommariva, M, additional, Sertoli, M R, additional, Simon, R, additional, Wang, E, additional, Rosenberg, S A, additional, and Marincola, F M, additional
- Published
- 2013
- Full Text
- View/download PDF
9. IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes
- Author
-
Murtas, D, primary, Maric, D, additional, De Giorgi, V, additional, Reinboth, J, additional, Worschech, A, additional, Fetsch, P, additional, Filie, A, additional, Ascierto, M L, additional, Bedognetti, D, additional, Liu, Q, additional, Uccellini, L, additional, Chouchane, L, additional, Wang, E, additional, Marincola, F M, additional, and Tomei, S, additional
- Published
- 2013
- Full Text
- View/download PDF
10. LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY
- Author
-
Yang, F. H., primary, Zhang, B., additional, Zhou, D. J., additional, Bie, L., additional, Tom, M. W., additional, Drummond, D. C., additional, Nicolaides, T., additional, Mueller, S., additional, Banerjee, A., additional, Park, J. W., additional, Prados, M. D., additional, James, D. C., additional, Gupta, N., additional, Hashizume, R., additional, Strohbehn, G. W., additional, Zhou, J., additional, Fu, M., additional, Patel, T. R., additional, Piepmeier, J. M., additional, Saltzman, W. M., additional, Xie, Q., additional, Johnson, J., additional, Bradley, R., additional, Ascierto, M. L., additional, Kang, L., additional, Koeman, J., additional, Marincola, F. M., additional, Briggs, M., additional, Tanner, K., additional, Vande Woude, G. F., additional, Tanaka, S., additional, Klofas, L. K., additional, Wakimoto, H., additional, Borger, D. R., additional, Iafrate, A. J., additional, Batchelor, T. T., additional, Chi, A. S., additional, Madhankumar, A. B., additional, Slagle-Webb, B., additional, Rizk, E., additional, Harbaugh, K., additional, Connor, J. R., additional, Sarkar, G., additional, Curran, G. L., additional, Jenkins, R. B., additional, Kurozumi, K., additional, Ichikawa, T., additional, Onishi, M., additional, Fujii, K., additional, Ishida, J., additional, Shimazu, Y., additional, Date, I., additional, Ebsworth, K., additional, Walters, M. J., additional, Ertl, L. S., additional, Wang, Y., additional, Berahovich, R. D., additional, Zhang, P., additional, Powers, J. P., additional, Liu, S.-C., additional, Al Omran, R., additional, Sullivan, T. J., additional, Jaen, J. C., additional, Brown, M., additional, Schall, T. J., additional, Yusuke, N., additional, Shimizu, S., additional, Shishido-Hara, Y., additional, Shiokawa, Y., additional, Nagane, M., additional, Wang, J., additional, Sai, K., additional, Chen, F.-R., additional, Chen, Z.-P., additional, Shi, Z., additional, Zhang, J., additional, Zhang, K., additional, Han, L., additional, Chen, L., additional, Qian, X., additional, Zhang, A., additional, Wang, G., additional, Jia, Z., additional, Pu, P., additional, Kang, C., additional, Kong, L.-Y., additional, Doucette, T. A., additional, Ferguson, S. D., additional, Hachem, J., additional, Yang, Y., additional, Wei, J., additional, Priebe, W., additional, Fuller, G. N., additional, Qiao, W., additional, Rao, G., additional, Heimberger, A. B., additional, Chen, P.-Y., additional, Ozawa, T., additional, Drummond, D., additional, Santos, R., additional, Torre, J. D., additional, Ng, C., additional, Lepe, E. L., additional, Butowski, N., additional, Prados, M., additional, Bankiewicz, K., additional, James, C. D., additional, Cheng, Z., additional, Gong, Y., additional, Ma, Y., additional, Muller-Knapp, S., additional, Knapp, S., additional, Antonio Chiocca, E., additional, Kaur, B., additional, Yu, J. S., additional, Judkowski, V., additional, Bunying, A., additional, Ji, J., additional, Li, Z., additional, Bender, J., additional, Pinilla, C., additional, Srinivasan, V., additional, Dombovy-Johnson, M., additional, Carson-Walter, E., additional, Walter, K., additional, Xu, Z., additional, Popp, B., additional, Schlesinger, D., additional, Gray, L., additional, Sheehan, J., additional, Keir, S. T., additional, Friedman, H. S., additional, Bigner, D. D., additional, Kut, C., additional, Tyler, B., additional, McVeigh, E., additional, Li, X., additional, Herzka, D., additional, Grossman, S., additional, Lasky, J. L., additional, Panosyan, E., additional, Meisen, W. H., additional, Hardcastle, J., additional, Wojton, J., additional, Wohleb, E., additional, Alvarez-Breckenridge, C., additional, Nowicki, M., additional, Godbout, J., additional, Lee, S. Y., additional, Sheehan, J. M., additional, Yin, S., additional, Kaluz, S., additional, Devi, S. N., additional, de Noronha, R., additional, Nicolaou, K. C., additional, Van Meir, E. G., additional, Lachowicz, J. E., additional, Demeule, M., additional, Che, C., additional, Tripathy, S., additional, Jarvis, S., additional, Currie, J.-C., additional, Regina, A., additional, Nguyen, T., additional, Castaigne, J.-P., additional, Zielinska-Chomej, K., additional, Mohanty, C., additional, Viktorsson, K., additional, Lewensohn, R., additional, Driscoll, J. J., additional, Alsidawi, S., additional, Warnick, R. E., additional, Rixe, O., additional, deCarvalho, A. C., additional, Irtenkauf, S., additional, Hasselbach, L., additional, Xin, H., additional, Mikkelsen, T., additional, Sherman, J. H., additional, Siu, A., additional, Volotskova, O., additional, Keidar, M., additional, Gibo, D. M., additional, Dickinson, P., additional, Robertson, J., additional, Rossmeisl, J., additional, Debinski, W., additional, Nair, S., additional, Schmittling, R., additional, Boczkowski, D., additional, Archer, G., additional, Sampson, J. H., additional, Mitchell, D. A., additional, Miller, I. S., additional, Didier, S., additional, Murray, D. W., additional, Issaivanan, M., additional, Coniglio, S. J., additional, Segall, J. E., additional, Al-Abed, Y., additional, Symons, M., additional, Fotovati, A., additional, Hu, K., additional, Triscott, J., additional, Bacha, J., additional, Brown, D. M., additional, Dunn, S. E., additional, Daniels, D. J., additional, Peterson, T. E., additional, Dietz, A. B., additional, Knutson, G. J., additional, Parney, I. F., additional, Diaz, R. J., additional, Golbourn, B., additional, Picard, D., additional, Smith, C., additional, Huang, A., additional, Rutka, J., additional, Saito, N., additional, Fu, J., additional, Yao, J., additional, Wang, S., additional, Koul, D., additional, Yung, W. K. A., additional, Yuan, Y., additional, Sulman, E. P., additional, Colman, H., additional, Lang, F. F., additional, Slat, E. A., additional, Herzog, E. D., additional, Rubin, J. B., additional, Carminucci, A. S., additional, Amendolara, B., additional, Leung, R., additional, Lei, L., additional, Canoll, P., additional, Bruce, J. N., additional, Wojton, J. A., additional, Chu, Z., additional, Kwon, C.-H., additional, Chow, L. M., additional, Palascak, M., additional, Franco, R., additional, Bourdeau, T., additional, Thornton, S., additional, Qi, X., additional, Kitange, G. J., additional, Mladek, A. C., additional, Su, D., additional, Carlson, B. L., additional, Schroeder, M. A., additional, Pokorny, J. L., additional, Bakken, K. K., additional, Gupta, S. K., additional, Decker, P. A., additional, Wu, W., additional, Sarkaria, J. N., additional, Oddou, M. P., additional, Mollard, A., additional, Call, L. T., additional, Vakayalapati, H., additional, Warner, S. L., additional, Sharma, S., additional, Bearss, D. J., additional, Chen, T. C., additional, Cho, H., additional, Wang, W., additional, Hofman, F. M., additional, Flores, C. T., additional, Snyder, D., additional, Sanchez-Perez, L., additional, Pham, C., additional, Friedman, H., additional, Woolf, E., additional, Abdelwahab, M. G., additional, Turner, G., additional, Preul, M. C., additional, Lynch, A., additional, Rho, J. M., additional, Scheck, A. C., additional, Salphati, L., additional, Heffron, T. P., additional, Alicke, B., additional, Barck, K., additional, Carano, R. A., additional, Cheong, J., additional, Greve, J., additional, Lee, L. B., additional, Nishimura, M., additional, Pang, J., additional, Plise, E. G., additional, Reslan, H. B., additional, Zhang, X., additional, GOuld, S. G., additional, Olivero, A. G., additional, Phillips, H. S., additional, Zadeh, G., additional, Jalali, S., additional, Voce, D., additional, Wei, Z., additional, Shijun, K., additional, Nikolai, K., additional, Josh, W., additional, Clayton, C., additional, Bakhtiar, Y., additional, Alkins, R., additional, Burgess, A., additional, Ganguly, M., additional, Wels, W., additional, Hynynen, K., additional, Li, Y. M., additional, Jun, H., additional, Daniel, V., additional, Walter, H. A., additional, Nakashima, H., additional, Nguyen, T. T., additional, Shalkh, I., additional, Goins, W. F., additional, Chiocca, E. A., additional, Pyko, I. V., additional, Nakada, M., additional, Furuyama, N., additional, Lei, T., additional, Hayashi, Y., additional, Kawakami, K., additional, Minamoto, T., additional, Fedulau, A. S., additional, and Hamada, J.-i., additional
- Published
- 2012
- Full Text
- View/download PDF
11. Immunologic markers associated with favorable prognosis in breast cancer patients: Role of innate immune system.
- Author
-
Ascierto, M. L., primary, Kmieciak, M., additional, Idowu, M. O., additional, Bedognetti, D., additional, De Maria, A., additional, Bear, H. D., additional, Wang, E., additional, Marincola, F., additional, and Manjili, M., additional
- Published
- 2011
- Full Text
- View/download PDF
12. 1194PTranslational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A).
- Author
-
Diamond, J R, Standifer, N, Ascierto, M L, Morehouse, C, Ghadially, H, Canales, J Rodriguez, Rebelatto, M C, Naidoo, J, Mazzarella, L, and Patel, S
- Subjects
- *
COLORECTAL cancer , *PHARMACEUTICAL biotechnology - Published
- 2018
- Full Text
- View/download PDF
13. NEMO-binding domain peptide inhibits proliferation of human melanoma cells.
- Author
-
Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, De Maio A, Ombra M, Gentilcore G, Capone M, Ascierto M, Satriano RA, Farina B, Faraone-Mennella M, Ascierto PA, and Ialenti A
- Subjects
- Cell Line, Tumor, Electrophoretic Mobility Shift Assay, Flow Cytometry, Humans, NF-kappa B metabolism, Cell Proliferation, I-kappa B Kinase physiology, Melanoma pathology
- Abstract
Melanoma is the most aggressive form of skin cancer, it originates from melanocytes and its incidence has increased in the last decade. Recent advances in the understanding of the underlying biology of the progression of melanoma have identified key signalling pathways that are important in promoting melanoma tumourigenesis, thus providing dynamic targets for therapy. One such important target identified in melanoma tumour progression is the Nuclear Factor-kappaB (NF-kappaB) pathway. In vitro studies have shown that NF-kappaB binding is constitutively elevated in human melanoma cultures compared to normal melanocytes. It has been found that a short cell-permeable peptide spanning the IKK-beta NBD, named NBD peptide, disrupted the association of NEMO with IKKs in vitro and blocked TNFalpha-induced NF-kappaB activation in vivo. In the present study we investigated the effect of the NBD peptide on NF-kappaB activity and survival of A375 human melanoma cells. We found that NBD peptide is able to inhibit the proliferation of A375 cells, which present constitutively elevated NF-kappaB levels. Inhibition of cell proliferation by NBD peptide was associated with direct inhibition of constitutive NF-kappaB DNA-binding activity and induction of apoptosis by activation of caspase-3 as confirmed by the cleavage and consequently inactivation of poly (ADP ribose) polymerase (PARP-1) known as the best marker of this process.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.